Firm's OTC and Rx products will be marketed and manufactured in Korea under joint venture with South Korean firm Heung-II Pharmaceutical, Sterling announced Aug. 22. The venture, to be known as Sterling Drug Korea Ltd., will also produce and market Heung-II's vitamin and OTC lines.
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?